Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
News and updates for Protalix BioTherapeutics, Inc. (PLX) center on its activities as a biopharmaceutical company focused on rare disease therapeutics and recombinant proteins produced with its proprietary ProCellEx® plant cell-based expression system. This page aggregates company press releases, financial announcements and clinical program updates that reflect how Protalix is developing and commercializing enzyme replacement therapies and advancing its pipeline.
Investors and followers of PLX can find coverage of commercial performance for the company’s approved products, including Elfabrio® for Fabry disease and Elelyso® (taliglucerase alfa) for Gaucher disease, supplied to partners such as Chiesi, Pfizer and Fiocruz in Brazil. News items also describe how these established revenue streams support Protalix’s research and development efforts.
Another key theme in Protalix news is pipeline progress. The company regularly reports on PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, including Phase 1 data and regulatory milestones like the submission of an IND to the FDA for a planned Phase 2 trial. Updates also cover PRX–119, a long-acting DNase I candidate for NETs-related and rare renal diseases, and the company’s collaboration with Secarna Pharmaceuticals to discover antisense oligonucleotide therapies for rare kidney indications.
Regulatory and corporate developments appear frequently in PLX news, such as EMA evaluations of new dosing regimens for Elfabrio, inclusion in the Russell 3000® and 2000® Indexes, at-the-market equity program amendments, executive appointments and outcomes of stockholder meetings or legal matters. Bookmark this page to follow how Protalix’s commercial partnerships, clinical trials and strategic collaborations evolve over time.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced its participation in the BTIG Virtual Biotechnology Conference on August 10-11, 2020. Dror Bashan, the CEO, will present in a fireside chat format on August 10 at 2:00 PM ET. The presentation can be viewed live on the company’s website and will be available for replay for 15 days. Protalix is known for its proprietary ProCellEx® system for producing therapeutic proteins and has a pipeline targeting diseases like Fabry disease and cystic fibrosis.
Protalix BioTherapeutics (NYSE: PLX) announced it will release its second quarter 2020 financial results and business update on August 10, 2020, at 8:30 a.m. EDT. A conference call with management will follow to discuss the results. Protalix, known for its ProCellEx® plant cell-based protein expression system, has developed recombinant therapeutic proteins, including taliglucerase alfa. The company has ongoing partnerships for product development, notably with Chiesi Farmaceutici for pegunigalsidase alfa aimed at Fabry disease.
Protalix BioTherapeutics (NYSE American: PLX) announced a non-binding term sheet with SarcoMed USA for the development of PRX-110 (alidornase alfa) targeting Pulmonary Sarcoidosis. This follows the FDA granting Orphan Drug Designation to alidornase alfa for the treatment of this rare disease on July 21, 2020. Protalix, known for its ProCellEx® plant-based protein expression system, seeks to advance its pipeline that includes various recombinant therapeutic proteins. The company has previously collaborated with Pfizer for another product, taliglucerase alfa.